| Objective:To analyze the expression of the breast cancer patients’ heat shock protein90α(HSP90α)in plasma,and to study the clinical value in the diagnosis of breast cancer.Methods:89 female breast cancer patients entirely in Wuhan Fourth Hospital from September 2019 to December 2021 were selected as the experimental group;76patients with benign breast disease as the control group;50 healthy females in physical examination center as the healthy control group.The expression level of HSP90α in these samples was detected by ELISA.At the same time,plasma concentrations of carcinoembryonic antigen(CEA)and tumor glycoprotein antigen15-3(CA15-3)were determined by electrochemiluminescence.Variance analysis was used to analyze the difference of plasma HSP90α distribution among the experimental group,experimental control group and healthy control group.Wilcoxon rank sum test was used to analyze the changes of plasma HSP90 a levels in breast cancer patients before and after treatment.Correlation analysis of spearman was used to explore the correlation of HSP90α in plasma with different clinicopathological data.ROC curve was used to explore the optimal critical point of plasma HSP90α in the diagnosis of breast cancer.Chi-square test was used to observe the efficacy of HSP90 a combined with CEA and CA15-3 in the diagnosis of breast cancer.The clinical experiments in this paper were approved by the Ethics Committee and were carried out in the Fourth Hospital of Wuhan.Results:The average of plasma HSP90α in breast cancer patients was 84.66ng/ml,which was higher than the average of 66.55ng/ml in the benign breast disease group,and was much higher than the average of HSP90α in the healthy control group as well,which was 55.80ng/ml;There is a significant positive correlation among the three groups(P<0.05);Besides,in peripheral blood,the average of HSP90α in the control group was higher than in the healthy control group,and there was a seriously difference between the two groups(P<0.05);indicating that the plasma HSP90α can be used as a tumor marker to identify the patient of breast cancer or benign breast diseases and healthy people.In peripheral blood,the concentration of HSP90α in breast cancer patients,before treatment was significantly higher than that after treatment,and there was a remarkably difference between the two groups(P<0.05);indicating that the expression of HSP90α in plasma may be related to the tumor burden of breast cancer.The expression level of HSP90α in plasma was significantly correlated with the TNM stage of breast cancer and whether the lymph node is metastasis or not(P<0.05);and the expression of HSP90α in plasma was higher when the TNM stage of breast cancer was more advanced;Patients of the breast cancer with lymph node invasions have higher plasma concentrations of HSP90α than those without lymph node invasions;however,in the tumor tissue,there was no positive correlation between HSP90α with the expression of estrogen receptor(ER),progesterone receptor(PR),human epidermalgrowth factorreceptor-2(HER-2)and molecular typing(P<0.05).In these experimental subjects,there was no positive correlation between the plasma HSP90α level with age and menstrual status(menopausal or not)(P<0.05).Selecting 61.375ng/ml as the critical value of HSP90αin plasma to diagnose breast cancer;after calculation,the area under the curve(AUC)was 0.864,and the sensitivity was 80.9%,the specificity was 84.0%,respectively.In comparison with CEA and CA15-3,the accuracy of HSP90α in breast cancer diagnosis was significantly higher than that of single traditional tumor markers;Furthermore,HSP90α combined with traditional tumor markers of breast cancer can significantly improve the accuracy of breast cancer diagnosis.Conclusion:HSP90α is highly expressed in the peripheral blood of breast cancer patients,and it can be a novel tumor marker,playing a role in the diagnosis of breast cancer. |
PDF Full Text Request